American Century Companies Inc. increased its position in shares of Biohaven Ltd. (NYSE:BHVN – Free Report) by 9.5% during ...
American Century Companies has boosted its stake in Biohaven (BHVN) by 9.5% during Q4, ETF Daily News reports, citing a recent SEC filing. The ...
Hosted on MSN1mon
Biohaven Just Hurdled An FDA Setback — And Its Moving LinesBiohaven stock hurdled its 50-day and 200-day lines Tuesday after the Food and Drug Administration granted its spinocerebellar ataxia treatment a speedier review time. Spinocerebellar ataxia ...
Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of total IgG, differentiating Biohaven's new small-molecule class of degraders from the monoclonal ...
Swiss National Bank raised its stake in shares of Biohaven Ltd. (NYSE:BHVN – Free Report) by 12.2% during the 4th quarter, ...
NEW YORK, NY / ACCESS Newswire / March 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...
Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial. The registrational study assessed BHV-7000, a drug designed to selectively activate Kv7.2/Kv7.3 ...
Morgan Stanley lowered the firm’s price target on Biohaven (BHVN) to $63 from $69 and keeps an Overweight rating on the shares. Biohaven reported Q4 earnings on March 3 and provided “mixed ...
In trading on Tuesday, shares of Biohaven Ltd (Symbol: BHVN) crossed above their 200 day moving average of $40.76, changing hands as high as $42.68 per share. Biohaven Ltd shares are currently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback